Industry Symposia Programme

Please see below the programme for the Industry Symposia during the BSH 2018 Annual Scientific Meeting.

Monday 16 April 16:30 - 17:30

Company

Session title & Speakers

Room Name

 

Amgen

Kyprolis®(carfilzomib) and dexamethasone in relapsed myeloma: real-world patient management

Chair: Rakesh Popat, London

Speakers:

Rakesh Popat, London

Christopher Plummer, Newcastle-upon-Tyne

Stephen Hawkins, Liverpool

Anne-Marie Kelly, Manchester

Cathy Williams, Nottingham

 

Room 2E

Gilead Sciences UK

Rethinking How We See – Addressing Current Questions and Controversies in relapse B-Cell lymphomas

Chair: Andy Pettitt, Liverpool

Speakers:

Stephen Devereux, London

Peter Hillmen, Leeds

Andy Pettitt, Liverpool

Anna Schuh, Oxford

 

Room 2L

Novartis

CML today and tomorrow

Speakers:

Jane Apperley, London

Susanne Saußele, Mannheim, Germany

Mhairi Copland, Glasgow

Adam Mead, Oxford

Richard Clark, Liverpool

 

Room 11B

Takeda

Navigating challenging cases in Hodgkin Lymphoma: an MDT approach

Chair: Graham Collins, Oxford

Speakers:

Graham Collins, Oxford

Wendy Osborne, Newcastle upon Tyne

Cathy Burton, Leeds

Stephen Robinson, Bristol

 

Room 11A

 

Monday 16 April 17:45 - 18:45

Company

Session Title & Speakers

Room Name

Servier

Cardiotoxic effects of Chemotherapies for Haematological Malignancies – What are the practical considerations?

Speakers:

Ruth Pettengell, London

Alex Lyon, London

 

Room 2E

Gilead Sciences UK

Emerging Cellular Therapies: Driving CAR-T outcomes and beyond

Chair: Andy Pettitt, Liverpool

Speakers:

David Linch, London

Robert Hawkins, Manchester

Andy Pettitt, Liverpool

Stephen Robinson, Bristol

 

Room 2L

Janssen

Multiple Myeloma – Aspiring to New Depths

Chair: Graham Jackson, Newcastle Upon Tyne

Speakers:

Graham Jackson, Newcastle Upon Tyne

Mark Cook, Birmingham

Rakesh Popat, London

 

Room 11B

NCRI AML

NCRI AML Trials - Evolving Strategies

Speakers:

Nigel Russell, Nottinghams

Mike Dennis, Manchester

Centre for Clinical Trials Research, Cardiff University

 

Room 11A

 

Tuesday 17 April 15:30 - 16:30

Company

Session title & Speakers

Room Name

Takeda

Spotlight on Myeloma: Giving real-world perspective to clinical evidence

Chair: Gordon Cook, Leeds

Speakers:

Gordon Cook, Leeds

Maria-Victoria Mateos, Salamanca, Spain

Karthik Ramasamy, Oxford

 

Room 2E

Alexion

Thrombosis and Complement Mediated Diseases

Speakers:

Tina Dutt, Liverpool

Marie Scully, London

Anita Hill, Leeds

 

Room 2L

AbbVie

Venetoclax into UK practice: real-world insights on BCRI failure & relapsed CLL

Chair: Anna Schuh, Oxford

Speakers:

George Follows, Cambridge

Chris Fox, Nottingham

Anna Schuh, Oxford

 

Room 11B

Bristol-Myers Squibb

Immune Response Mechanisms: The Next Wave in CML Research

Chair: Mhairi Copland, Glasgow

Speakers:

Satu Mustjoki, Helsinki, Finland

Hugues de Lavallade, London

 

Room 11A

 

Tuesday 17 April 16:45 - 17:45

Company

Session title & Speakers

Room Name

Novartis

What Every Haematologist Should Know About CAR T Cell Therapy

Speaker:

Shannon Maude, Philadelphia, US

 

Room 2E

Daiichi Sankyo

Cancer and the burden of VTE

Chair: Henry Watson, Aberdeen

Speakers:

Cihan Ay, Vienna, Austria

Jecko Thachil, Manchester

 

Room 2L

Roche Products Limited

Evolving Strategies in NHL

Chair: Stephen Robinson, Bristol

Speakers:

Stephen RobinsonBristol

Wendy Osborne, Newcastle Upon Tyne

Anna Schuh, Oxford

 

Room 11B

Shire Pharmaceuticals

 From 9 to 90, haematological presentations of Gaucher disease; illustrated by case studies

Speaker:

Derralynn Hughes, London

 

Room 11A